The Georgia Institute of Technology will play a key role in a new federally backed initiative to advance medications made from cells, such as vaccines and autoimmune drugs, as well as therapies using living cells to treat a range of conditions.

A $15.7 million grant from the Atlanta-based Marcus Foundation has helped launch a new Georgia Institute of Technology research center that will develop processes and techniques for ensuring the consistent, low-cost, large-scale manufacture of high-quality living cells used in cell-based therapies.

An industry-driven consortium has developed a national roadmap designed to chart the path to large-scale manufacturing of cell-based therapeutics for use in a broad range of illnesses including cancer, neuro-degenerative diseases, blood and vision disorders and organ regeneration and repair.

Krishnendu Roy scanned the room, taking note of the people all around him in the Vatican, and thought, “what the heck am I doing here?”

The vision of making affordable, high-quality cell-based therapies available to hundreds of thousands of patients worldwide moved closer to reality June 6 with the dedication of a new cell manufacturing research facility at Georgia Tech aimed at changing the way we think about medical therapies.

Doctors knew long before Owen Webb was born that they were racing against the clock to save his life.

At Georgia Tech, we’re on it. From cell manufacturing and clean energy to cybersecurity and cures for diseases, we’re partnering on campus and around the world, creating the next.